Difference between revisions of "Ramosetron (Iribo)"
Jump to navigation
Jump to search
m |
m |
||
(One intermediate revision by one other user not shown) | |||
Line 3: | Line 3: | ||
==Also known as== | ==Also known as== | ||
− | *'''Brand names:''' IBset, Iribo, Nasea, Nozia | + | *'''Brand names:''' IBset, Iribo, Irribow, Nasea, Nozia |
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Emesis prevention]] | [[Category:Emesis prevention]] | ||
[[Category:Serotonin 5-HT3 antagonists]] | [[Category:Serotonin 5-HT3 antagonists]] | ||
− | [[Category:PMDA approved | + | [[Category:PMDA approved in 2015]] |
Latest revision as of 01:27, 11 June 2023
Mechanism of action
Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. Not FDA-approved; available in Japan and Southeast Asia.
Also known as
- Brand names: IBset, Iribo, Irribow, Nasea, Nozia